Shareholder rights law firm Robbins LLP informs investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) (a) common stock pursuant to the Company's February 13, 2025 initial public offering ("IPO") and/or (b) securities between February 13, 2025 and May 14, 2026 (the "Class Period"). Aardvark is a clinical-stage biopharmaceutical company that focuses on developing small-molecule therapies designed to inhibit hunger and treat metabolic diseases such as Prader-Willi Syndrome (“PWS”), a neurodevelopmental disorder condition that presents hyperphagia, or a feeling of extreme, insatiable hunger.
NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
SAN DIEGO, May 14, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has placed a full clinical hold on its investigational new drug application (IND) for ARD-101 related to the Company’s previously announced voluntary pause. The clinical hold applies to all ongoing clinical studies under the IND, including the Phase 3 HERO trial (AVK-101-301) evaluating ARD-101 for the treatment of hyperphagia in patients with Prader-Willi Syndrome (PWS) and the Phase 3 open-label extension (OLE) trial (AVK-101-302). The Company remains in active discussions with the FDA to support resolution of the clinical hold and determine a path forward for the ARD-101 program.
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (Nasdaq: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NYSE: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
LOS ANGELES, March 04, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or “the Company”) (NASDAQ: AARD) for violations of the securities laws.
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Aardvark Therapeutics shares saw brokerage downgrades after the company paused its Phase 3 trial to treat hyperphagia in patients with Prader-Willi syndrome.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or “the Company”) (NASDAQ: AARD) for violations of the securities laws.
